Status:

UNKNOWN

Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer

Lead Sponsor:

University of Rome Tor Vergata

Conditions:

Prostate Cancer

Eligibility:

MALE

46-86 years

Phase:

NA

Brief Summary

Short-term Efficacy of Transperineal Laser Ablation (TPLA) with Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an interventional pilot study....

Detailed Description

Short-term Efficacy of Transperineal Laser Ablation (TPLA) With Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an interventional pilot study....

Eligibility Criteria

Inclusion

  • Male
  • Over 45 years old
  • Prostate cancer identified after prostatic biopsy with fusion of images with target and systematic samples (\> 12)
  • Intermediate progression risk (Gleason Score 3 + 4 or 4 + 3; PSA \<15 ng / ml; clinical stage T1-T2a)
  • Low risk of progression (Gleason score 3 + 3) only in patients who wish to leave or who refuse the active surveillance protocol and who refuse validated treatments for the treatment of organo-confined prostate cancer: radical surgery and / or radiotherapy

Exclusion

  • Prostate cancer Gleason Score\> = 4 + 4.
  • Clinical stage\> T2a
  • PSA\> 15 ng / ml
  • Presence of metastases from prostate lymph node, bone or visceral carcinoma detected by bone scintigraphy, total body CT or PET-CT
  • Serious coagulation disorders not correctable
  • Unavailable or replaceable anticoagulant and / or antiplatelet therapy
  • Inadequate compliance
  • Presence of pacemakers
  • Contraindications to MRI (claustrophobia, ear implants, metal prostheses)
  • Paramagnetic contrast agent allergy
  • Acute and / or chronic renal failure (GFR \<50 mL / min and serum creatinine\> 1.5 mg / dl)
  • Tumor volume \<15 ml measured on MRI

Key Trial Info

Start Date :

August 2 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 2 2024

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04045756

Start Date

August 2 2019

End Date

August 2 2024

Last Update

December 17 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Policlinico Tor Vergata (PTV) Foundation: Department di Biomedicine and Prevention

Rome, RM, Italy, 00133

Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer | DecenTrialz